Empowering effective biomarker-driven precision oncology: A call to action

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Precision oncology relies on biomarkers for cancer diagnosis, prognosis, and treatment prediction.
• Genomic testing advances are not fully integrated into clinical practice, hindering optimal patient care.
• Delays in biomarker testing availability and implementation limit access to life-saving therapies.

Purpose of the Study:

• To highlight the critical role of biomarkers in precision oncology.
• To identify barriers impeding the routine adoption of biomarker testing.
• To advocate for the integration of precision genomic testing into standard oncology care.

Main Methods:

• Review of current challenges in biomarker testing implementation.
• Analysis of factors hindering diagnostic pathways.
• Synthesis of evidence supporting cost-effectiveness of precision oncology.

Main Results:

• Genomic testing is underutilized in clinical practice, leading to missed treatment opportunities.
• Barriers include cost, reimbursement issues, limited access, regulatory hurdles, and assay validation needs.
• Precision oncology can be cost-effective, even in resource-limited settings.

Conclusions:

• Biomarker testing is essential for personalized cancer care and drug development.
• Routine integration of precision genomic testing is necessary for improved patient outcomes.
• Recommendations and a call to action are needed to mainstream biomarker-informed oncology.